DNA Repair Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR (2024 - 2029) | 13.20 % |
| Fastest Growing Market | North America |
| Largest Market | Asia-Pacific |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
DNA Repair Drugs Market Analysis
The DNA Repair Drugs Market is expected to register a CAGR of 13.20% during the forecast period.
The DNA repair drugs market is expected to grow significantly over the forecast period owing to factors such as the growing burden of cancer worldwide and increasing research and development for novel drugs and treatments. The incidence and prevalence of various types of cancer are increasing due to lifestyle changes along with the factors that increase the risk of developing cancer, such as increasing consumption of alcohol and smoking, obesity, as well as a family history of cancer. This is expected to boost the demand and the need to develop effective and safe DNA repair cancer drugs, propelling the market’s growth.
For instance, according to data published by the International Agency for Research on Cancer in February 2024, the overall prevalence of cancer cases globally was reported to be 14.1 million in 2022, with the highest in Asia, amounting to 6.4 million, followed by 3.5 million in Europe. Thus, the increased number of cancer cases among the population further fuels the demand for DNA repair drugs, propelling the market’s growth.
Furthermore, companies' rising focus on researching and developing novel drugs for treating cancer also contributes to market growth. For instance, in February 2024, the National Cancer Institute (NCI) funded new research to target lethal prostate cancer by exploring the role of BRCA2 “DNA damage repair genes” to create new therapeutics. Thus, new funding for developing new DNA repair drugs is expected to boost the market significantly over the forecast period.
Therefore, the market studied is expected to grow over the forecast period due to factors such as the high prevalence of cancer and the rising focus on research and development activities. However, the strict regulation of product approvals will likely impede the growth of the DNA repair drugs market over the forecast period.
DNA Repair Drugs Market Trends
Olaparib Segment Expected to Hold a Significant Share in the Market Over Forecast Period
Olaparib is a base-excision repair (BER) enzyme inhibitor that prevents poly-ADP ribose polymerase (PARP), which is involved in the repair of DNA damage caused by oxidative stress. Olaparib is sold under the brand name Lynparza. The advantages offered by Lynparza, such as its demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS), reducing the risk of cancer recurrences, second cancers or death, and high progression-free-survival rate, over the other DNA repair drugs (rucaparib, niraparib, and others) raises its adoption in cancer treatment. This is anticipated to fuel the segment's growth over the forecast period.
The combination usage of olaparib with other oncology drugs is increasing the efficacy in cancer treatment, which is likely to increase the usage of olaparib, thereby boosting segment growth over the forecast period. For instance, an article published in the Clinical Cancer Research journal in January 2024 reported that olaparib with durvalumab and bevacizumab demonstrated notable clinical activity in women with non-gBRCAm platinum-sensitive relapsed ovarian cancer (PSROC). These combination treatments are expected to increase the usage of olaparib and increase its adoption during cancer treatments, which, in turn, is anticipated to fuel the segment’s growth over the forecast period.
Furthermore, increasing product approvals raise the availability of effective DNA repair drugs in the market, which is also contributing to market growth. For instance, in May 2023, AstraZeneca Pharmaceuticals received approval from the US Food and Drug Administration (FDA) for olaparib (Lynparza) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
Therefore, owing to factors such as rising product approvals and increasing adoption of olaparib due to its numerous advantages over other drugs, the segment studied is expected to grow over the forecast period.
North America Expected to Hold a Significant Share in the Market Over the Forecast Period
North America is expected to witness significant growth in the DNA repair drugs market over the forecast period owing to factors such as the increasing focus on research and development, the growing number of investments in DNA repair research, and the growing burden of cancer in the region.
The increasing incidence and prevalence of various cancers among the population boost the demand for DNA repair drugs, which is anticipated to fuel market growth. For instance, according to 2024 statistics published by the American Cancer Society, about 2.00 million new cancer cases (1.03 million males and 0.97 million females) are expected to be diagnosed in the United States in 2024, compared to 1.96 million cases in 2023. This shows the increasing incidence of cancer cases in the United States, which is expected to drive the usage of DNA repair drugs, thereby boosting market growth over the forecast period in the region.
Additionally, according to statistics published by the Canada Cancer Society, an estimated 239 thousand Canadians were reported with new cancer cases in 2023. As per the same source, lung and bronchus cancer is the most prevalent malignancy in Canadians. Hence, the high burden of cancer cases among the population is expected to increase the demand for effective treatment options, which is anticipated to propel market growth in the region.
Furthermore, the increasing activities in developing cancer drugs also contribute to market growth. For instance, in July 2023, AstraZeneca received a Notice of Compliance with Conditions (NOC/c) from Health Canada for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC). Therefore, the market studied is expected to grow over the forecast period due to factors such as the high burden of cancer and increasing research activities, which are likely to boost the demand for DNA repair drugs in the region.
DNA Repair Drugs Industry Overview
The DNA repair drugs market is fragmented, with the presence of several global market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. These activities expand and increase the availability of products in various countries globally, which is likely to boost market growth. Some of the key players in the market are AstraZeneca PLC, Clovis Oncology, GSK PLC, Pfizer Inc., and Onxeo, among others.
DNA Repair Drugs Market Leaders
-
AstraZeneca plc
-
Clovis Oncology
-
Pfizer Inc.
-
Onxeo
-
GSK plc
*Disclaimer: Major Players sorted in no particular order
DNA Repair Drugs Market News
- January 2024: Pfizer Inc. received approval from the European Commission (EC) for TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI (enzalutamide) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
- November 2023: pharmaand GmbH (pharma&) received approval from the European Commission (EC) for a Type II variation for Rubraca (rucaparib) as a first-line maintenance treatment for all women with advanced ovarian cancer who have responded to first-line platinum-based chemotherapy, regardless of their BRCA mutation status.
DNA Repair Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Burden of Cancer Worldwide
- 4.2.2 Increasing Research and Development for Novel Drugs and Treatment
-
4.3 Market Restraints
- 4.3.1 Strict Regulations for Product Approval
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Drug Type
- 5.1.1 Olaparib
- 5.1.2 Rucaparib
- 5.1.3 Niraparib
- 5.1.4 Talazoparib
- 5.1.5 Other Drug Types
-
5.2 By Application
- 5.2.1 Ovarian Cancer
- 5.2.2 Fallopian Tube Cancer
- 5.2.3 Peritoneal Cancer
- 5.2.4 Breast Cancer
- 5.2.5 Other Applications
-
5.3 By Distribution Channel
- 5.3.1 Hospital Pharmacies
- 5.3.2 Retail Pharmacies
- 5.3.3 Other Distribution Channels
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Rest of the World
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Onxeo
- 6.1.2 FoRx Therapeutics
- 6.1.3 Artios Pharma Limited
- 6.1.4 Merck KGaA
- 6.1.5 Breakpoint Therapeutics
- 6.1.6 Luciole Pharmaceuticals
- 6.1.7 AstraZeneca PLC
- 6.1.8 AbbVie
- 6.1.9 Johnson & Johnson
- 6.1.10 Pfizer Inc.
- 6.1.11 ClovisOncology Inc.
- 6.1.12 GSK PLC
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityDNA Repair Drugs Industry Segmentation
As per the scope of the report, DNA repair drugs are the drugs that are majorly used in treating cancers. DNA repair drugs are known to inhibit DNA repair enzymes and kill cancer cells with defects in DNA repair due to mutations in DNA repair genes.
The DNA repair drugs market is segmented by drug type, application, distribution channel, and geography. By drug type, the market is segmented into olaparib, rucaparib, niraparib, talazoparib, and other drug types. By application, the market is segmented into ovarian cancer, fallopian tube cancer, peritoneal cancer, breast cancer, and other application types. The other applications segment includes prostate cancer, pancreatic cancer, etc. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and other distribution channels. By geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The market report also covers the estimated market sizes and trends for 13 different countries across major regions globally. The report offers the value (USD) for the above segments.
| By Drug Type | Olaparib | |
| Rucaparib | ||
| Niraparib | ||
| Talazoparib | ||
| Other Drug Types | ||
| By Application | Ovarian Cancer | |
| Fallopian Tube Cancer | ||
| Peritoneal Cancer | ||
| Breast Cancer | ||
| Other Applications | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Other Distribution Channels | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Rest of the World |
DNA Repair Drugs Market Research FAQs
What is the current DNA Repair Drugs Market size?
The DNA Repair Drugs Market is projected to register a CAGR of 13.20% during the forecast period (2024-2029)
Who are the key players in DNA Repair Drugs Market?
AstraZeneca plc, Clovis Oncology, Pfizer Inc., Onxeo and GSK plc are the major companies operating in the DNA Repair Drugs Market.
Which is the fastest growing region in DNA Repair Drugs Market?
North America is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in DNA Repair Drugs Market?
In 2024, the Asia-Pacific accounts for the largest market share in DNA Repair Drugs Market.
What years does this DNA Repair Drugs Market cover?
The report covers the DNA Repair Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the DNA Repair Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
DNA Repair Drugs Industry Report
Statistics for the 2024 DNA Repair Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. DNA Repair Drugs analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
